Form 8-K - Current report:
SEC Accession No. 0001193125-25-135860
Filing Date
2025-06-05
Accepted
2025-06-05 16:04:18
Documents
12
Period of Report
2025-06-05
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d920336d8k.htm   iXBRL 8-K 32993
  Complete submission text file 0001193125-25-135860.txt   143472

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA amlx-20250605.xsd EX-101.SCH 2847
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE amlx-20250605_lab.xml EX-101.LAB 17235
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE amlx-20250605_pre.xml EX-101.PRE 10810
14 EXTRACTED XBRL INSTANCE DOCUMENT d920336d8k_htm.xml XML 3505
Mailing Address 43 THORNDIKE STREET CAMBRIDGE MA 02141
Business Address 43 THORNDIKE STREET CAMBRIDGE MA 02141 617-683-0917
Amylyx Pharmaceuticals, Inc. (Filer) CIK: 0001658551 (see all company filings)

EIN.: 464600503 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41199 | Film No.: 251027055
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)